SCHEMBL19409246

SCHEMBL19409246

CCNc1ncn(C)c1NC

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.49
ALDH1A1 P00352 1/20 0.44
YTHDC1 Q96MU7 2/20 0.38
KDM4E B2RXH2 2/20 0.38
PGK1 P00558 2/20 0.35
IKBKB O14920 2/20 0.35
CHUK O15111 2/20 0.35
SYK P43405 5/20 0.33
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
POLB P06746 1/20 0.32
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19409225 0.88 SMN1; SMN2 (0.56) SMN1; SMN2ALDH1A1YTHDC1KDM4EPGK1
SCHEMBL19409235 0.86 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1YTHDC1KDM4EPGK1
SCHEMBL19409234 0.83 ALDH1A1 (0.50) SMN1; SMN2ALDH1A1YTHDC1IKBKBCHUK
SCHEMBL19409262 0.78 PGK1 (0.34) SMN1; SMN2ALDH1A1KDM4EPGK1POLB
SCHEMBL19409218 0.76 SMN1; SMN2 (0.41) SMN1; SMN2KDM4EPGK1IKBKBCHUK
SCHEMBL25658511 0.73 SMN1; SMN2 (0.54) SMN1; SMN2ALDH1A1KDM4EIKBKBCHUK
SCHEMBL27967127 0.73 ALDH1A1 (0.46) SMN1; SMN2ALDH1A1YTHDC1PDE4APDE4B
SCHEMBL19409251 0.72 SMN1; SMN2 (0.53) SMN1; SMN2ALDH1A1KDM4ESYKPOLB
SCHEMBL19827043 0.70
SCHEMBL19420515 0.69 SMN1; SMN2 (0.36) SMN1; SMN2ALDH1A1YTHDC1KDM4EPGK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170281501-A1 4,5-DIAMINOIMIDAZOLES AS NOVEL DEVELOPER-TYPE OXIDATION DYE PRECURSORS HENKEL AG & CO. KGAA (DE) 2017-10-05 US claimed
US-20170281501-A1 4,5-DIAMINOIMIDAZOLES AS NOVEL DEVELOPER-TYPE OXIDATION DYE PRECURSORS HENKEL AG & CO. KGAA (DE) 2017-10-05 US disclosed
US-20170281501-A1 4,5-DIAMINOIMIDAZOLES AS NOVEL DEVELOPER-TYPE OXIDATION DYE PRECURSORS HENKEL AG & CO. KGAA (DE) 2017-10-05 US disclosed
US-20170281501-A1 4,5-DIAMINOIMIDAZOLES AS NOVEL DEVELOPER-TYPE OXIDATION DYE PRECURSORS HENKEL AG & CO. KGAA (DE) 2017-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170281501-A1 4,5-DIAMINOIMIDAZOLES AS NOVEL DEVELOPER-TYPE OXIDATION DYE PRECURSORS KRT18, DHODH, AOC1 SMN1; SMN2 4868/4885ALDH1A1 45/4885YTHDC1 3771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.